Progress in Medicinal Chemistry: Volume 29

·
· Progress in Medicinal Chemistry Libro 29 · Elsevier
Libro electrónico
349
Páxinas
Apto
As valoracións e as recensións non están verificadas  Máis información

Acerca deste libro electrónico

The 29th volume of the series presents yet again, an exemplary survey of a wide range of current topics in medicinal chemistry and pharmacology. Eight expert reviews emphasize the relationships between chemical structure and pharmacological activity. These detailed discussions of some of the most exciting developments in the field today, will prove of great value to future research. The book begins with a study of anti-inflammatory activities of 5-lipoxygenase inhibitors, followed by an overview of the antiarrhythmic therapeutic possibilities offered by Class III electrophysiological agents. Structures and activities of some opioid ligands are surveyed, and the investigation into pharmacologically active pyridazine derivatives is continued. Dopamine D2 receptor agonists offer exciting therapeutic potential, as do ondansetron and related 5-HT 3 antagonists. The herbal origin of many modern drugs is yet again reflected in a survey of the herb feverfew. The volume concludes, as it began, with enzyme inhibition - in this case concerning synthetic inhibitors of interstitial collagenases.

Valora este libro electrónico

Dános a túa opinión.

Información de lectura

Smartphones e tabletas
Instala a aplicación Google Play Libros para Android e iPad/iPhone. Sincronízase automaticamente coa túa conta e permíteche ler contido en liña ou sen conexión desde calquera lugar.
Portátiles e ordenadores de escritorio
Podes escoitar os audiolibros comprados en Google Play a través do navegador web do ordenador.
Lectores de libros electrónicos e outros dispositivos
Para ler contido en dispositivos de tinta electrónica, como os lectores de libros electrónicos Kobo, é necesario descargar un ficheiro e transferilo ao dispositivo. Sigue as instrucións detalladas do Centro de Axuda para transferir ficheiros a lectores electrónicos admitidos.